سعر بونفوري 2 الى 10 مجم 14 قرص 2023

Ponvory 2 to 10 mg 14 f.c.tabs. (treatment-initiation pack)

معلومات الدواء

دواعي الاستعمالUses

Relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease) in adults.الفئة: AdultsDailyMed (U.S. National Library of Medicine)

Relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease) in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)

الآثار الجانبيةSide effects

Most common adverse reactions (at least 10%): upper respiratory tract infection, hepatic transaminase elevation and hypertension.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

Most common adverse reactions (at least 10%): upper respiratory tract infection, hepatic transaminase elevation and hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)

موانع الاستعمالContraindications

In the last 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
Mobitz type II second-degree or third-degree AV block, sick sinus syndrome or sino-atrial block, unless a functioning pacemaker is present.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

In the last 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Mobitz type II second-degree or third-degree AV block, sick sinus syndrome or sino-atrial block, unless a functioning pacemaker is present.International label, same formulation · DailyMed (U.S. National Library of Medicine)

تحذيرات واحتياطاتWarnings & precautions

Infections: may increase infection risk; obtain a CBC before starting, do not start during active infection, and monitor for infection during treatment and for 1-2 weeks after stopping.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
Bradyarrhythmia and AV conduction delays at initiation: titration is required; first-dose 4-hour monitoring for patients with sinus bradycardia, first- or second-degree (Mobitz I) AV block, or prior MI/heart failure.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
Other warnings: decline in pulmonary function, liver injury, increased blood pressure, cutaneous malignancies (skin examination recommended), and fetal risk (effective contraception during treatment and for about 1 week after stopping).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

Infections: may increase infection risk; obtain a CBC before starting, do not start during active infection, and monitor for infection during treatment and for 1-2 weeks after stopping.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Bradyarrhythmia and AV conduction delays at initiation: titration is required; first-dose 4-hour monitoring for patients with sinus bradycardia, first- or second-degree (Mobitz I) AV block, or prior MI/heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Other warnings: decline in pulmonary function, liver injury, increased blood pressure, cutaneous malignancies (skin examination recommended), and fetal risk (effective contraception during treatment and for about 1 week after stopping).International label, same formulation · DailyMed (U.S. National Library of Medicine)

الحمل والرضاعةPregnancy & breastfeeding

No adequate studies in pregnant women; in rats and rabbits ponesimod caused embryolethality and fetal malformations at clinically relevant exposures. Women of childbearing potential should use effective contraception.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
No data on presence in human milk; consider benefits of breastfeeding against the mother's need for ponesimod and potential infant effects.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

No adequate studies in pregnant women; in rats and rabbits ponesimod caused embryolethality and fetal malformations at clinically relevant exposures. Women of childbearing potential should use effective contraception.International label, same formulation · DailyMed (U.S. National Library of Medicine)
No data on presence in human milk; consider benefits of breastfeeding against the mother's need for ponesimod and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

مادة فعالة مختلفة من نفس المجموعة العلاجية. لا تستبدل دواءك ببديل إلا بأمر الطبيب.

بدائل بونفوري 2 الى 10 مجم 14 قرص من نفس المجموعة العلاجية بمادة فعالة مختلفة، مرتبة من الأرخص
الدواء	السعر
مايزينت 0.25 مجم 12 قرصMayzent 0.25 mg 12 film-coated tabletsNovartis Pharma Scientific Office · قرص مغلف · 0.25 mg	السعر2,197ج.م183.08ج.م للوحدة
سفينجومود 0.5 مجم 28 كبسولةSphingomod 0.5 mg capsulesHikma Specialized Pharmaceuticals · كبسولة · 0.5 mg	السعر6,634ج.م236.93ج.م للوحدة
فينليمود 5.مجم 28 كبسولةFinlimod 0.5 mg 28 capsBiogeneric Pharma · كبسولة · 0.5 mg	السعر7,137ج.م254.89ج.م للوحدة
جيلينيا 0.5 مجم 28 كبسولةGilenya 0.5mg 28 capsNovartis · كبسولة صلبة · 0.5 mg	السعر16,850ج.م601.79ج.م للوحدة
مايزنت 0.25مجم 120 قرصMayzent 0.25 mg 120 film-coated tabletsNovartis Pharma Scientific Office · قرص مغلف · 0.25 mg	السعر19,465ج.م162.21ج.م للوحدة
ماي زنت 2مجم 28 قرصMayzent 2 mg 28 film-coated tabletsNovartis Pharma Scientific Office · قرص مغلف · 2 mg	السعر20,630ج.م736.79ج.م للوحدة

لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.